ArticleJournal of gastrointestinal cancer2022
The Characters of Graphene Oxide Nanoparticles and Doxorubicin Against HCT-116 Colorectal Cancer Cells In Vitro.
Article in Journal of gastrointestinal cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 24 citations in OpenAlex.
- Nanoparticles for Doxorubicin Delivery: Advances in Carrier Design and Synergistic Cancer Therapy.Topics in current chemistry (Cham) · 2026Review
- Pyrrolidine-based hybrid compounds: design, synthesis, in vitro and in vivo pharmacological properties and molecular docking studies.Future medicinal chemistry · 2025Article
- The application of various carbon nanoparticle injection methods in sentinel lymph node mapping for colorectal cancer.European journal of medical research · 2025Article
- Preparation and Evaluation of pH-Sensitive Chitosan/Alginate Nanohybrid Mucoadhesive Hydrogel Beads: An Effective Approach to a Gastro-Retentive Drug Delivery System.Pharmaceutics · 2024Article
- The application of graphene oxide and ferroptosis in the diagnosis and treatment of colorectal cancer: a narrative review.Journal of gastrointestinal oncology · 2024Review
- Synthesis of Artemether-Loaded Albumin Nanoparticles and Measurement of Their Anti-Cancer Effects.Biomedicines · 2022Article
- Evaluation of Methylation Panel in the Promoter Region ofArchives of Razi Institute · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeColorectal cancer (CRC) is among the leading causes of cancer death worldwide. Graphene oxide (GO) plus doxorubicin (DOX) have low toxicity and facilitate drug carriage and provide enough surface. The GO-DOX anticancer effects against HCT-116 human CRC cells were compared with that of pure GO and DOX compounds.
methodsDifferent concentrations of graphene oxide (GO), doxorubicin (DOX), and graphene oxide plus doxorubicin (GO-DOX) were prepared. The MTT test was conducted to determine the viability of cells and flow cytometry was performed following DOX, GO, and GO-DOX exposure. Expressions of caspase 3, Bax, and ATG5 autophagy-related genes were investigated using RT-qPCR technique.
resultsIn the MTT test, DOX and GO at 100 µg/mL and 40 µg/mL exerted 50% cell death (LC50) against the HCT-116 cells. We observed significant differences in GO-DOX LC50 at concentrations of 1 (p = 0.003), 2.5 (p = 0.003), 5 (p = 0.00009), and 10 µg/mL (p = 0.0001). The rate of apoptosis following GO, DOX, and GO-DOX included 24%, 31%, and 56%, respectively. The GO-DOX significantly increased the ATG5 (3.1-fold, p < 0.0001), caspase 3 (4.7-fold, p < 0.0001), and Bax (4.3-fold, p < 0.0001) gene expression.
conclusionThe GO-DOX exerted anticancer effects against the HCT-116 cells via inducing the apoptosis and autophagy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.